

## **Plain language summary**

Idiopathic pulmonary fibrosis (IPF) is a disease that causes scarring of patients' lungs and cannot be cured. There is a need for new drugs to improve the care of patients with IPF. BI 1015550 was developed to help slow the lung damage in patients with IPF. Two clinical trials were performed; one in healthy volunteers and one in patients with IPF, and any medical problems the participants had during the trials were recorded. In the clinical trials, common medical problems were headache and effects on the digestive tract, but overall BI 1015550 seemed to be safe to use. This means BI 1015550 can be looked at in other clinical trials to see if it could be a useful treatment for IPF.